Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-FC516 in Prostate Cancer
NCT07542379Phase 1Recruiting
- Sponsor
- FindCure Biosciences
- Start
- Aug 2026
- Primary completion
- May 2027
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 177Lu-FC516 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by FindCure Biosciences. Primary endpoints: Dose-Limiting Toxicity at 42 days, Adverse Events and Serious Adverse Events at 12 months and 1 more. Started Aug 2026; status: recruiting.
02
Drugs
177Lu-FC516
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07542379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07542379.